Evidence map›Paper›PMID 27330535›Full record

ArticleFrontiers in microbiology2016

Novel Synthesis of Kanamycin Conjugated Gold Nanoparticles with Potent Antibacterial Activity.

Jason N Payne, Hitesh K Waghwani, Michael G Connor, William Hamilton, Sarah Tockstein, Harsh Moolani, Fenil Chavda, Vivek Badwaik, Matthew B Lawrenz, Rajalingam Dakshinamurthy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 145 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jason N PayneDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Hitesh K WaghwaniDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Michael G ConnorCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases and the Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville KY, USA.
William HamiltonDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Sarah TocksteinDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Harsh MoolaniDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Fenil ChavdaDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Vivek BadwaikDepartment of Chemistry, Western Kentucky University, Bowling Green KY, USA.
Matthew B LawrenzCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases and the Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville KY, USA.
Rajalingam DakshinamurthyDepartment of Chemistry, Western Kentucky University, Bowling GreenKY, USA; Department of Chemistry, Austin Peay State University, ClarksvilleTN, USA.
Western Kentucky University · USUniversity of Louisville · USAustin Peay State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With a sharp increase in the cases of multi-drug resistant (MDR) bacteria all over the world, there is a huge demand to develop a new generation of antibiotic agents to fight them. As an alternative to the traditional drug discovery route, we have designed an effective antibacterial agent by modifying an existing commercial antibiotic, kanamycin, conjugated on the surface of gold nanoparticles (AuNPs). In this study, we report a single-step synthesis of kanamycin-capped AuNPs (Kan-AuNPs) utilizing the combined reducing and capping properties of kanamycin. While Kan-AuNPs have increased toxicity to a primate cell line (Vero 76), antibacterial assays showed dose-dependent broad spectrum activity of Kan-AuNPs against both Gram-positive and Gram-negative bacteria, including Kanamycin resistant bacteria. Further, a significant reduction in the minimum inhibitory concentration (MIC) of Kan-AuNPs was observed when compared to free kanamycin against all the bacterial strains tested. Mechanistic studies using transmission electron microscopy and fluorescence microscopy indicated that at least part of Kan-AuNPs increased efficacy may be through disrupting the bacterial envelope, resulting in the leakage of cytoplasmic content and the death of bacterial cells. Results of this study provide critical information about a novel method for the development of antibiotic capped AuNPs as potent next-generation antibacterial agents.

Indexed as

antibacterial activityantibiotic resistancecharacterizationgold nanoparticleskanamycin

Identifiers

PMID27330535
PMCPMC4908860
OpenAlexW2461840561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.